与阿尔茨海默氏症病原发生相关的生物标志物
Hui Wang1, Mengli Sun1,2, Wenhui Li1
1College of Life Sciences, Nankai University, Tianjin, China.
Frontiers in cellular neuroscience
|December 22, 2023
概括
对阿尔茨海默病 (AD) 的早期诊断至关重要. 本综述研究了AD病理学的生物标志物,包括粉样蛋白和蛋白,以改善疾病监测和治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,具有复杂的,相互作用的病理.
- 目前的诊断方法往往在晚期发现AD,从而限制了早期干预.
- 了解AD病原体是开发有效生物标志物的关键.
研究的目的:
- 审查阿尔茨海默病的发病因子,重点关注AT(N) 生物标志物系统.
- 评估大脑脊髓液 (CSF) 和AD的血液生物标志物的当前研究状态.
- 讨论AD幽默标记的局限性和未来方向.
主要方法:
- 关于AD病原和生物标志物研究的文献综述.
- 对粉样沉积 (A),病理 (T) 和神经退行 (N) 标志物的研究分析.
- 在AD中探索新兴领域,如线粒体功能障碍和肠道微生物组.
主要成果:
- 亚丁氨酸 (AT) 系统 (粉样蛋白,氨酸,神经退行) 包括经过验证的AD诊断核心幽默标志物.
- 大脑脊髓液 (CSF) 和血液生物标志物对早期AD检测有希望.
- 线粒体功能障碍,子病毒学和肠道微生物组越来越多地被认为与AD病变发生相关.
结论:
- 生物标志物对于早期的AD查,诊断和监测疾病进展至关重要.
- 需要进一步开发幽默标记物,以克服目前的诊断局限性.
- 对阿尔茨海默病的多维理解,包括新的因素,将提高诊断的准确性.
相关概念视频
01:26Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
94
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
94